Monopar Therapeutics
Monopar Therapeutics (MNPR) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 213 transactions totaling $45.1M, demonstrating a bearish sentiment with -$32.6M in net insider flow. The most recent transaction on Jan 1, 2026 involved a transaction of 2,000 shares valued at $0.
MNPR Insider Activity Summary
Who Is Buying MNPR Stock?
No significant insider buying has been recorded for MNPR in the recent period.
Who Is Selling MNPR Stock?
No significant insider selling has been recorded for MNPR in the recent period.
Is Monopar Therapeutics Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for MNPR is bearish with an Insider Alignment Score of 14/100 and a net flow of -$32.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
MNPR Frequently Asked Questions
Understanding MNPR Insider Activity
Insider trading at Monopar Therapeutics (MNPR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading MNPR stock, having executed 213 transactions in the past 90 days. The most active insider is Pharma Llc Tactic (Executive), who has made 6 transactions totaling $36.8M.
Related Tools
Track Monopar Therapeutics Insider Activity
Get notified when executives and directors at MNPR file new Form 4 transactions